Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.
Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.
Neurol Med Chir (Tokyo). 2021 Jul 15;61(7):393-396. doi: 10.2176/nmc.st.2021-0018. Epub 2021 May 24.
The effectiveness of adenosine-induced flow arrest in surgical clipping for the cerebral aneurysms with difficulties in temporary clip placement to the proximal main trunk has been reported. This is the first clinical trial to evaluate the safety and feasibility of adenosine-assisted clipping surgery for unruptured cerebral aneurysms (UCAs) in Japan. The inclusion criteria are as follows: patients over 20 years old, patients who agree to be enrolled in this study after providing informed consent, patients who undergo clipping surgery for UCA in our institute, and patients in whom the surgeons (T.H. or I.D.) judge that decompression of the aneurysm is effective. The primary endpoint is a modified Rankin Scale (mRS) score 30 days after surgery. We plan to enroll 10 patients in this study. The original protocol of adenosine administration was established in this trial. Herein, we present the study protocol.
腺苷诱导血流停止在近端主干难以临时夹闭的脑动脉瘤夹闭术中的有效性已有报道。这是在日本首次评估腺苷辅助夹闭手术治疗未破裂脑动脉瘤（UCAs）的安全性和可行性的临床试验。纳入标准如下：年龄超过 20 岁，患者在提供知情同意后同意参加本研究，患者在我院接受 UCA 夹闭手术，以及术者（T.H.或 I.D.）判断动脉瘤减压有效的患者。主要终点是术后 30 天改良 Rankin 量表（mRS）评分。我们计划在这项研究中招募 10 名患者。腺苷给药的原始方案是在这项试验中建立的。在此，我们介绍研究方案。
